ITALIAN LIFE-SCIENCES COMPANY
ACS Biomed develops proprietary programs across antiviral dermatology, ophthalmology and renal-care MedTech, alongside six consumer health platforms spanning joint, oral, women’s and men’s health.
Commercial products · Clinical-stage pharmaceuticals · MedTech innovation · Consumer health platforms
View distribution opportunitiesDermatology
Antiviral topical care
Ophthalmology
Ocular surface immunomodulation
Renal Care
Portable MedTech
Consumer Health
Joint, oral, women’s and men’s health
International expansion across Europe, Latin America, the Gulf and Africa.
Four proprietary assets across antiviral dermatology, ophthalmology and renal care — each with a distinct commercial or development opportunity.
10
Proprietary assets & platforms
7
Therapeutic areas
5
Platforms launch-ready 2026–27
1
Ongoing Phase IIb program
International commercial and development activity across Europe, Latin America, the Gulf and Africa.
Topical nanoemulsion for recurrent genital HSV-2. EU and UK cosmetic notifications completed, available for commercialization now, with a Phase IIb head-to-head study vs. acyclovir underway.
Distribution · Licensing · Co-development
Cosmetic cream for cold-sore lesions on the lip area. CPNP and UK.GOV notifications completed, ready for distributor onboarding in new regional markets.
Regional Distribution
Tacrolimus-based ophthalmic galenic solution for Keratoconjunctivitis Sicca, with no direct equivalent in the galenic ophthalmic market. Phase III initiation is the next value-inflection point.
Licensing · Clinical Co-development
Portable continuous-flow hemodialysis system in a suitcase format, with proportional blending control and integrated safety electronics under active engineering development.
Industrial Partnership · Licensing
A consistent development approach applied across every therapeutic area — from unmet need to partnership-ready asset.
We start from documented clinical or engineering gaps with limited or no effective solutions on the market.
IP-protected formulations, devices or protocols are built internally with specialized development partners.
Each asset advances through structured clinical, regulatory or engineering validation aligned with EMA/FDA and CE pathways.
At each value-inflection point, we choose the path — direct commercialization, licensing, or co-development — that best serves the asset.
Independent development
Core science and IP are developed and controlled internally before any partnership discussion.
Selective partnership
We engage partners deliberately, at the stage and structure that maximizes value for each asset.
Every program has a specific, actionable partnership opportunity — choose the asset that fits your interest.
Clinical development activity is separate from commercial and partnership activity — both are shown below.
Active Phase IIb clinical sites for ErpeCream® across Europe.
Regions with signed distribution agreements, active regulatory/commercial development, or open territory for new partners.
An Italian biotech company transforming science into global health
ACS Biomed, headquartered in Udine, develops innovative solutions for unmet medical needs in dermatology, ophthalmology, and nephrology.
Udine, Italy
Strategic position in the heart of Europe, with access to major pharmaceutical markets
ACS Biomed founded in Udine, Italy
ErpeCream Phase I completion
EU & US patent portfolio secured
Phase II data (97% efficacy at 96h)
CPNP notification (EU) and UK.GOV notification for dermocosmetic
Gulf & UK expansion
Phase IIb preparation with Top Tier CRO partner (Thermo Fisher PPD)
Phase IIb execution: 80 patients, Aciclovir comparison
To transform promising scientific research into accessible therapies for patients worldwide, combining Italian excellence in pharmaceutical research with a global vision.
Differentiated nanoemulsion technology supported by scientific and clinical development
Made in Italy excellence in every product
Solutions available to all patients
Collaboration for global growth
Focused internal leadership supported by a specialized international development network.
International business development activities continue as the company strengthens its global commercial and pharmaceutical network.
Read More
Observational clinical experience collected by an independent physician contributes additional real-world insights into the use of ErpeCream® in patients with recurrent HSV infections.
Read More
International multicentre clinical trial supports the pharmaceutical development of ErpeCream® and future regulatory strategy.
Read MoreACS Biomed actively seeks strategic partners for licensing, co-development, and regional commercialization across its pharmaceutical and medtech portfolio.